《诺华公司Novartis AG (NVS) 2012年年度报告「NYSE」.pdf》由会员分享,可在线阅读,更多相关《诺华公司Novartis AG (NVS) 2012年年度报告「NYSE」.pdf(284页珍藏版)》请在三个皮匠报告上搜索。
1、ANNUAL REPORT 20121We want to discover,develop andsuccessfully market innovativeproducts to prevent and curediseases,to ease suffering andto enhance the quality of life.We also want to provide ashareholder return that reflectsoutstanding performance andto adequately reward thosewho invest ideas and
2、work inour company.cONTENTsOUR missiONGROUP REviEWFinancial Highlights2News in 20123Letter from Daniel vasella5interview with Joseph Jimenez11HEALTHcARE PORTFOLiOcontents17Pharmaceuticals21Novartis institutes for Biomedical Research33Alcon37sandoz47vaccines and Diagnostics53consumer Health59cORPORAT
3、E REsPONsiBiLiTycontents65Expanding Access to Healthcare67Doing Business Responsibly77independent Assurance Report85cORPORATE GOvERNANcEcontents87Our Board of Directors96Our management110cOmPENsATiON REPORTcontents121compensation Report122NOvARTis GROUPFiNANciAL REPORTcontents147Financial Highlights
4、 2012148Key Financial Developments149Operating and Financial Review150share information168summary of Key Financial Data188Novartis Group consolidated Financial statements190Financial statements of Novartis AG258Annual Report Photography and Films278Key Dates 2013,contact information280and Forward-Lo
5、oking statementsKEY FIGURES(in USD millions,unless indicated otherwise)SHARE INFORMATION20122011Net sales56 67358 566Operating income11 51110 998Return on net sales(%)20.318.8Net income9 6189 245Basic earnings per share1(USD)3.933.83Core operating income215 16015 909Core return on net sales(%)26.727
6、.2Core net income212 81113 490Core earnings per share1,2(USD)5.255.57Core Research&Development29 1169 239As a%of net sales16.115.8Number of associates(FTE)3127 724123 686Group free cash flow11 38312 50320122011Share price at year end(CHF)57.4553.70ADS price at year end(USD)63.3057.17Dividend4(CHF)2.